Evidence map›Paper›PMID 28150447›Full record

ReviewJournal of cosmetic dermatology2017

Chemotherapy-induced alopecia management: Clinical experience and practical advice.

Alfredo Rossi, Maria Caterina Fortuna, Gemma Caro, Giulia Pranteda, Valentina Garelli, Umberto Pompili, Marta Carlesimo

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cosmetic dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Trial
  5. The use of photobiomodulation therapy for the management of chemotherapy-induced alopecia: a randomized, controlled trial (HAIRLASER trial).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Cancer-Related Alopecia Risk and Treatment.Current treatment options in oncology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alfredo RossiDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Maria Caterina FortunaDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Gemma CaroDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Giulia PrantedaDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Valentina GarelliDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Umberto PompiliDepartment of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Marta CarlesimoDermatology, "Sapienza" University of Rome, II School, Rome, Italy.
Sapienza University of Rome · ITUniversity of Rome Tor Vergata · IT

Funding

Intramural NIH HHS NIH0010513932Wellcome Trust
6 · The paper itself

Abstract

backgroundChemotherapy-induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment-related aspects such as drug dose, administration regimen, and exposure to X-rays, but also patient-related characteristics. To the best of our knowledge, no guidelines are available about CIA management. AIMS AND

methodsWith this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists. RESULTS AND

conclusionThere is an urgent need for prospective studies to clarify the mechanistic basis of alopecia associated with these drugs and consequently to design evidence-based management strategies.

Indexed as

AlopeciaAntineoplastic AgentsHumansMolecular Targeted TherapyPractice Guidelines as TopicProtein Kinase InhibitorsRisk AssessmentAntineoplastic AgentsProtein Kinase Inhibitorschemotherapeutic drugshair lossskin reactions

Identifiers

PMID28150447
PMCPMC5540831
OpenAlexW2584431284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.